
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is a clinical-stage biotechnology company that boasts a strong pipeline of potentially groundbreaking therapies and a proprietary cell-based manufacturing platform. With increasing revenue and growing operational progress, the company has seen a net income for the first quarter in 2025. Upcoming catalysts, such as further clinical data releases and the potential for additional non-dilutive capital, could drive further success for Lineage Cell Therapeutics, making it a promising investment opportunity.
Bears say
Lineage Cell Therapeutics is a clinical-stage biotechnology company with a pipeline focused on degenerative diseases, but its most advanced asset, OpRegen, faces several key risks in clinical/regulatory, financial, commercial, legal/intellectual property, and market share spheres. While the company's partnerships display commitment and have brought in milestone revenue, the milestone's division with the Israel Innovation Authority and Hadasit suggests that its prior funding and collaboration structures have reduced potential net cash benefit. Additionally, OpRegen's positive findings are far from definitive, and trading indications remain slow to emerge.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares